Risk factors
Lyell Immunopharma (LYEL) risk factors
Item 1A of every Lyell Immunopharma, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors57 risks8 new13 dropped32 reworded
Lyell is advancing cell therapy candidates like ronde-cel and LYL273 while managing clinical, manufacturing, and collaboration risks.
Filed Mar 12, 2026 - FY2024 10-K risk factors62 risks
Lyell is a clinical-stage biopharmaceutical company focused on T-cell therapies and the recently acquired IMPT-314 candidate. The company has incurred substantial net losses, has no approved products, and depends heavily on additional capital. Operations face risks from complex manufacturing processes, clinical trial execution, regulatory approvals, and intellectual property protection.
Filed Mar 11, 2025